Victory Square Technologies Inc · CSE:VST
Victory Square Technologies — Investor Presentation (June 2026)
21 slides from Victory Square Technologies's investor presentation, June 2026
Slide 1: Victory Square Technologies
Victory Square Technologies Building The Infrastructure Layer Behind The Next Generation Of Healthcare Companies June 2026, Investor Presentation BUILD. SCALE. MONETIZE. REPEAT. CSE: VST | OTCQX: VSQTF | FSE: 6F6
Slide 2: Disclaimer
Disclaimer Disclaimer FORWARD LOOKING INFORMATION This Presentation contains “forward-looking information” and “forward looking statements” within the meaning of applicable securities laws and (collectively, “forward-looking statements”). Forward-looking statements in this Presentation include, but
Slide 3: Why This Webinar
WEBINAR PURPOSE Why This Webinar Why We Believe Victory Square Is Positioned Differently Today Than At Any Point In Its History STRONGER BALANCE SHEET PROVEN HEALTHCARE INFRASTRUCTURE MULTIPLE PATHS TO UNLOCK VALUE The market may be valuing Hydreight today. We believe it is only beginning to value w
Slide 4: Who Is Victory Square?
COMPANY DEFINITION Who Is Victory Square? NOT IS VC Fund Venture Builder ETF Capital Allocator Passive Holding Company Operator Mutual Fund Healthcare Infrastructure Platform Most investors still misunderstand what VST actually is.
Slide 5: The Venture Creation Flywheel
The Venture Creation Flywheel THE MODEL A repeatable system designed to compound capital through infrastructure, scale, and monetization. 01 02 03 Identify Opportunity Build Infrastructure Scale Find markets where infrastructure Assemble capital, compliance, and Drive adoption through shared can unl
Slide 6: Capital Allocation Is Our Product
CAPITAL ALLOCATION Capital Allocation Is Our Product ANCHOR OUTCOME — HYDREIGHT FANSUNITE Invested ~$2M $6M+ A history of small initial positions, strategic asset COVALENT Invested ~$50K ~$1M sales, and outcomes that demonstrate the platform’s compounding logic. ARGO BLOCKCHAIN Invested ~$79K $1.4M+
Slide 7: Why Healthcare?
HEALTHCARE THESIS Why Healthcare? DIABETES OBESITY LONGEVITY The Largest Opportunity We’ve Ever Pursued $4.5T+ US HEALTHCARE DIAGNOSTICS HORMONE HEALTH TELEHEALTH PEPTIDES We aren’t chasing products. We’re building infrastructure.
Slide 8: The Healthcare Operating System
OPERATING SYSTEM The Healthcare Operating System CORE LAYER Healthcare Infrastructure Platform CLINICAL NETWORK REGULATORY & TECHNOLOGY COMMERCIAL REACH PHYSICIANS 300+ DIAGNOSTICS Laboratory Network BRANDS 600–700 NURSES 3,000+ OVERSIGHT Compliance Infrastructure CLINICS Thousands LICENSES 12,000+
Slide 9: Why Hydreight Succeeded
Why Hydreight Succeeded Most Healthcare Startups Build One Piece. Hydreight Built The Entire Stack. This infrastructure took years to build. Every future healthcare opportunity starts with this advantage. 01 02 Physicians Compliance 03 04 Pharmacies Technology Hydreight Built 05 06 The Entire Stack.
Slide 10: Hydreight: Proof The System Works
PROOF POINT Hydreight: Proof The System Works The First Large-Scale Validation Of The Victory Square Model $24.9M Q1 REVENUE $27.6M ADJUSTED REVENUE $3.3M ADJUSTED EBITDA $2.6M NET INCOME $24.2M CASH $32.0M WORKING CAPITAL 12,000+ LICENSES SOLD 23.9M VST OWNERSHIP SHARES ~$109M VST OWNERSHIP VALUE H
Slide 11: The Hydreight Flywheel
ECOSYSTEM FLYWHEEL 01 02 The Hydreight Hydreight Growth More brands, clinics, patients, and VSDHOne Adoption Infrastructure usage expands across the Flywheel transaction volume. platform. 03 04 A platform loop where transaction volume, 10% Profit Share To VST New Healthcare Investments infrastructur
Slide 12: Why The Next Decade Could Be Bigger Than The Last
PLATFORM BRIDGE Why The Next Decade Could Be Bigger Than The Last THEN NOW NEXT Building Infrastructure Exists Leverage The Platform Infrastructure Relationships Exist Acquire Building Physicians Platform Exists Build Building Pharmacies Hydreight Validated The Model Invest Building Compliance Accel
Slide 13: Victory Square At A Glance
VST SNAPSHOT Victory Square At A Glance ESTIMATED NAV NAV PER SHARE MARKET CAPITALIZATION ~$170M ~$1.63 ~$71M SHARE PRICE CASH & MARKETABLE SECURITIES PUBLIC PORTFOLIO PRIVATE PORTFOLIO RESIDUAL ASSETS ~$0.68 ~$31M ~$116M ~$40M ~$14M A simplified snapshot of the numbers investors need Numbers as of
Slide 14: The Value Gap
THE VALUE GAP The Value Gap ESTIMATED NAV BREAKDOWN Hydreight ~$109M Public Investors Are Buying At A Significant Discount To Private Portfolio ~$40M NAV Residual IP ~$14M The NAV story becomes tangible when the underlying pieces are separated and compared with Marketable Securities ~$5.2M the curre
Slide 15: The Digital Health Accelerator
HEALTHCARE PIPELINE The Digital Health Accelerator Where Future Opportunities Come From DEAL FLOW WHY THIS MATTERS — THEY HAVE BUT OFTEN LACK Hundreds Of Companies Reviewed ✓Customers ✓Physicians Hundreds Of Founder Conversations ✓Revenue ✓Pharmacies Multiple Active Opportunities ✓Demand ✓Compliance
Slide 16: A New Approach To Peptide Delivery
Insu Therapeutics A New Approach To Peptide Delivery Insu is positioned around a patent-pending buccal delivery platform designed to reduce the friction of injection-based peptide therapy. TRADITIONAL INJECTION PATENT-PENDING PLATFORM Traditional Injection Patent-Pending Buccal Delivery Platform KEY
Slide 17: Why Insu Matters
PLATFORM POTENTIAL Why Insu Matters CATEGORY CATEGORY CATEGORY CATEGORY CATEGORY Insulin GLP-1 GLP-3 Hormones Future The Opportunity Is Bigger Peptides Than Any Single Molecule DELIVERY LAYER INSU PLATFORM Molecule-agnostic potential MULTIPLE PAYLOADS FLOWING INTO ONE DELIVERY SYSTEM If Hydreight Is
Slide 18: Applying The Healthcare Playbook To Pet Health
Pawsible Ventures Applying The Healthcare Playbook To Pet Health Hydreight For Humans. Pawsible For Pets. 400+ 8 $10M APPLICATIONS COMPANIES SELECTED FUND 6-Week Incubator Venture Studio Global Advisory Board COHORT 1 Applying The Healthcare Playbook To Pet Health. HYDREIGHT FOR HUMANS. PAWSIBLE FOR
Slide 19: How Value Gets Unlocked
VALUE UNLOCK How Value Gets Unlocked OPERATING & ASSET CATALYSTS CAPITAL MARKET OUTCOMES 01 Hydreight Growth Spin-Outs 01 02 10% VSDHOne Profit Share CONVERTED INTO Share Distributions 02 SHAREHOLDER VALUE 03 Asset Monetizations Buybacks 03 04 Strategic Transactions NAV Growth 04 Operating growth, a
Slide 20: Capital Allocation Priorities
CAPITAL PRIORITIES Capital Allocation Priorities A disciplined framework for redeploying capital where it can create the greatest long-term value per share. 01 02 Grow Existing Winners Invest In High Conviction CONCENTRATE RESOURCES AROUND VALIDATED OPERATING ASSETS Healthcare Opportunities USE THE
Slide 21: The Market Sees A Portfolio. We See A Platform.
CLOSING THESIS The Market Sees A Portfolio. We See A Platform. Hydreight validated it. Insu is leveraging it. Pawsible is applying it. New healthcare companies are entering it. The infrastructure is built. Now comes the compounding. BUILD. SCALE. MONETIZE. REPEAT. CSE VST OTCQX VSQTF FSE 6F6
Victory Square Technologies — Investor Presentation (June 2026) on 6ix